| 영문 | IDDM(Insulin-Dependent Diabetes Mellitus) | 한글 | 인슐린의존당뇨병 |
|---|---|---|---|
| 설명 | IDDM은 당뇨병의 치료에 반드시 인슐린이 필요한 경우를 말한다. 주로 원인이 이자에 있는 인슐린을 분비하는 세포의 파괴이며 이로 인해서 당뇨병의 치료제로 쓰이는 인슐린의 분비를 촉진하는 약물이 이 IDDM에서는 쓰일 수가 없고 오직 인슐린만이 치료제로 쓸 수가 있다. 전형적인 인슐린 의존형 당뇨병은 소아에서 흔히 발생하고 인슐린 분비세포의 파괴에 의해서 인슐린 분비능은 거의 없다. |
||
| 영문 | complement | 한글 | 보체 |
|---|---|---|---|
| 설명 | 항체와 반응하여 항체와 결합된 세포의 파괴를 일으키는 단백질을 말한다. 항체가 항체와 결합한 세포를 파괴하는 방법에는 여러 가지가 있는데 그 중의 하나로 항체와 결합한 세포의 표면을 부분적으로 손상시켜 그 세포를 파괴하는 역할을 하는 것이 이 보체이다. 보체는 20가지의 단백질로 구성되어 있는데 약자로 C로 표시하며 각 종류를 나타낼 경우에는 C옆에 숫자를 써서 표시한다. |
||
| 영문 | complement fixation reaction | 한글 | 보체결합 반응, 도움체결합반응 |
|---|---|---|---|
| 설명 | 항체와의 반응에 있어서 보체와 결합하는 항체를 검사하는 방법으로, 이 반응은 최초에 기지항원, 피검혈청 및 보체를 혼합한다. 제2단계에서는 적혈구와 이것에 대응하는 용혈소의 혼합액을 가한다. 본 반응후 용혈이 일어나지 않으면 본체는 항원항체결합물에 결합한 것이 되어 양성이 되지만, 용혈이 일어난 경우 보체는 결합하지 않아 소비되지 않기 때문에 음성이 된다. 본 반응은 기지혈청을 써서 항원검출에 응용할 수 있으며, 마이코플라스마, 리케챠, 클라미디아, 바이러스, 매독 등의 진단에 쓰인다. |
||
| CDC | calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division... |
|---|---|
| ADCC cell | Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell |
| ADCC | acute disorder of cerebral circulation; antibody-dependent cell-mediated cytotoxicity |
| ADLC | antibody-dependent lymphocyte-mediated cytotoxicity |
| LDCC | lectin-dependent cellular cytotoxicity |
| CDC | Complement dependent cytotoxicity |
|---|---|
| CAMC | Complement-dependent antibody-mediated cytotoxicity |
| ADCC | Antibody Dependent Cell Cytotoxicity |
| ADCC | Antibody Dependent Cell-Mediated Cytotoxicity |
| ADCC | Antibody Dependent Cellular Cytotoxicity |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
|---|---|
| cytotoxicity | The quality or state of being cytotoxic. Antibody-dependent cell-mediated cytotoxicity (ADCC), a form of lymphocyte-mediated cytotoxicity that functions only if antibodies are bound to the target cell. Lymphocyte-mediated cytotoxicity, the toxic or lytic activity of T-lymphocytes, which may or may not be mediated by antibodies. Cytotoxic T lymphocytes may cause lysis of cells by production of cytolytic proteins such as perforin. B-cells may cause lysis of cells by antibody-complement binding to a target cell. Natural killer cells are cytotoxic without prior sensitization. Toxicity by lymphocytes may also be mediated by antibodies; there are three kinds of cytotoxic T-lymphocytes: those that are antigen-specific as a result of previous allergization (immunization), killer cells, and natural killer cells. See: antibody-dependent cell-mediated cytotoxicity. (05 Mar 2000) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
| complement 1q | <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors. Chemical name: Complement C1q (12 Dec 1998) |
| complement 1r | <enzyme> Subcomponent of complement 1 which, when activated by c1q, activates subcomponent c1s by proteolytic cleavage. Registry number: EC 3.4.21.41 (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|